This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechs: Archive
Vanda (VNDA) Falls on FDA's CRL to Hetlioz sNDA for Insomnia
by Zacks Equity Research
Vanda's (VNDA) supplemental new drug application seeking approval for Hetlioz to treat insomnia gets a complete response letter from the FDA.
VNDAPositive Net Change ANIPPositive Net Change ADMAPositive Net Change INDVPositive Net Change
biotechs
Gilead (GILD) & MRK's HIV Oral Combo Shows Efficacy in Phase II
by Zacks Equity Research
Gilead (GILD) and Merck's (MRK) phase II study data demonstrates the efficacy of their oral once-weekly combination of islatravir and lenacapavir in maintaining viral suppression in individuals with HIV.
BMYPositive Net Change JNJNegative Net Change MRKNegative Net Change GILDPositive Net Change
biotechs pharmaceuticals
Iterum (ITRM) Plans Early Submission of UTI Drug NDA, Stock Up
by Zacks Equity Research
Iterum (ITRM) stock rises as the company gears up to submit a regulatory application to the FDA seeking approval for oral sulopenem to treat adult women with uUTIs ahead of schedule.
ACETPositive Net Change ADMAPositive Net Change FGENNegative Net Change ITRMNegative Net Change
biotechnology biotechs medical pharmaceuticals
REGENXBIO (RGNX) Soars 15% on Interim Data From DMD Study
by Zacks Equity Research
Data from an early-stage study shows that treatment with REGENXBIO's (RGNX) investigational Duchenne therapy RGX-202 demonstrates early evidence of strength and motor function improvement.
SRPTPositive Net Change ADMAPositive Net Change RGNXPositive Net Change SLDBPositive Net Change
biotechs gene-therapy medical pharmaceuticals
Alnylam (ALNY), Roche's Blood Pressure Drug Meets Study Goal
by Zacks Equity Research
Data from a mid-stage study shows that Alnylam (ALNY) and Roche-partnered zilebesiran, when added to standard-of-care, lowers blood pressure significantly in adults with mild-to-moderate hypertension.
GSKPositive Net Change ALNYPositive Net Change RHHBYPositive Net Change ADMAPositive Net Change
biotechs medical pharmaceuticals
Bayer (BAYRY) Q4 Earnings Top, Crop Science Unit Drives Revenues
by Zacks Equity Research
Bayer (BAYRY) beats earnings estimates in the fourth quarter of 2023, primarily driven by increased sales of Crop Science and Pharmaceuticals products.
REGNPositive Net Change JNJNegative Net Change BAYRYPositive Net Change ADMAPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Here's Why You Should Invest in Aldeyra (ALDX) Stock Now
by Zacks Equity Research
Here, we discuss some reasons why investing in Aldeyra Therapeutics (ALDX) stock now may turn out to be a prudent move.
ALDXPositive Net Change COLLNegative Net Change LYRAPositive Net Change INDVPositive Net Change
biotechs
Novo Nordisk (NVO) Down Despite Kidney Outcomes Study Success
by Zacks Equity Research
Novo Nordisk (NVO) declines 3% despite achieving the primary endpoint with statistical significance in the FLOW outcomes study evaluating the efficacy of Ozempic 1 mg to treat CKD indication.
NVONegative Net Change ACETPositive Net Change ADMAPositive Net Change ETNBPositive Net Change
biotechnology biotechs medical pharmaceuticals
Akero (AKRO) Up on Upbeat Week 96 Data From Liver Disease Study
by Zacks Equity Research
Akero (AKRO) reports positive results from its mid-stage study of efruxifermin in pre-cirrhotic metabolic dysfunction-associated steatohepatitis patients at week 96. The stock gains 12%.
ACETPositive Net Change ADMAPositive Net Change AKROPositive Net Change ETNBPositive Net Change
biotechnology biotechs medical pharmaceuticals
Finding Cheap Stocks Under $10 to Buy in March
by Benjamin Rains
Along with the cheap price tags, the stocks we learn how to search for earn strong Zacks Ranks, driven by improving earnings outlooks
ADMAPositive Net Change ALITPositive Net Change
biotechs medical tech-stocks
FDA Lifts Clinical Hold on Iovance's (IOVA) Lung Cancer Study
by Zacks Equity Research
The FDA removes the clinical hold on Iovance's (IOVA) mid-stage study on LN-145 in certain NSCLC patients after reviewing the company's proposal for additional safety measures and monitoring.
ACETPositive Net Change PBYIPositive Net Change ADMAPositive Net Change IOVANegative Net Change
biotechs medical
Arcturus (ARCT) Stock Surges 73% in 3 Months: Here's Why
by Zacks Equity Research
Arcturus' (ARCT) steady progress with its product candidate, ARCT-032, for the treatment of cystic fibrosis is encouraging.
ARCTNegative Net Change VNDAPositive Net Change KNSAPositive Net Change INDVPositive Net Change
biotechs
J&J (JNJ) Secures Full FDA Nod for Rybrevant in Lung Cancer
by Zacks Equity Research
The approval is based on data from a late-stage study wherein treatment with J&J's (JNJ) Rybrevant plus chemotherapy reduced the disease-progression risk or death by 61% in certain NSCLC patients.
JNJNegative Net Change ACETPositive Net Change PBYIPositive Net Change ADMAPositive Net Change
biotechs medical pharmaceuticals
Viatris' (VTRS) Generic Declines in Q4, Yupleri Sales Rise
by Zacks Equity Research
Viatris (VTRS) stock down after posting weaker-than-expected results from its generics business. Nevertheless, the guidance for 2024 looks encouraging.
ACETPositive Net Change PBYIPositive Net Change ADMAPositive Net Change VTRSNegative Net Change
biotechs earnings pharmaceuticals
Ocuphire (OCUP) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Ocuphire (OCUP) is expected to provide updates on the clinical development of its lead retinal product candidate, APX3330, to treat diabetic retinopathy, in fourth-quarter 2023 earnings release.
VTRSNegative Net Change CGEMNo Net Change
biotechnology biotechs earnings medical pharmaceuticals
Puma Biotechnology (PBYI) Q4 Earnings & Revenues Lag Estimates
by Zacks Equity Research
Puma Biotechnology's (PBYI) fourth-quarter 2024 earnings and revenues fall shy of estimates. Stock declines.
PBYIPositive Net Change VNDAPositive Net Change KNSAPositive Net Change INDVPositive Net Change
biotechs earnings
Amarin's (AMRN) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Amarin's (AMRN) fourth-quarter 2023 earnings and revenues beat estimates. Vascepa's sales in the United States decline year over year.
ACETPositive Net Change AMRNPositive Net Change PBYIPositive Net Change ADMAPositive Net Change
biotechs earnings medical
Xenon (XENE) Q4 Earnings Top Estimates, Pipeline in Focus
by Zacks Equity Research
Xenon (XENE) reports mixed fourth-quarter 2023 financial results, wherein earnings beat estimates but revenues missed the same. Its development programs for XEN1101 in epilepsy and MDD are progressing well.
ACETPositive Net Change ADMAPositive Net Change XENEPositive Net Change AKROPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Pacira (PCRX) Q4 Earnings Match, Exparel Sales Drive Revenues
by Zacks Equity Research
Pacira (PCRX) reports fourth-quarter 2023 results, wherein earnings match and revenues beat estimates, driven by strong Exparel sales.
ACETPositive Net Change PCRXPositive Net Change ADMAPositive Net Change AKROPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Sarepta (SRPT) Q4 Earnings Beat Estimates, Revenues Up Y/Y
by Zacks Equity Research
Sarepta's (SRPT) Q4 earnings and sales beat estimates on the back of strong sales for recently-approved DMD gene therapy Elevidys.
RHHBYPositive Net Change ACETPositive Net Change SRPTPositive Net Change PBYIPositive Net Change
biotechs earnings gene-therapy medical pharmaceuticals
Catalyst (CPRX) Q4 Earnings & Sales Beat Estimates, Stock Up
by Zacks Equity Research
Catalyst (CPRX) reports encouraging fourth-quarter results, driven by Firdapse and Fycompa sales. The stock gains in the pre-market session.
ACETPositive Net Change CPRXNegative Net Change PBYIPositive Net Change ADMAPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Mirum's (MIRM) Q4 Earnings Lag Estimates, Revenues Beat
by Zacks Equity Research
Mirum's (MIRM) earnings fall shy of estimates in the fourth quarter of 2023 while revenues beat the same.
PBYIPositive Net Change VNDAPositive Net Change MIRMPositive Net Change INDVPositive Net Change
biotechs earnings
Amicus' (FOLD) Q4 Earnings Beat, Revenues Meet Estimates
by Zacks Equity Research
Amicus' (FOLD) fourth-quarter earnings beat estimates while revenues meet the same. Stock down.
FOLDPositive Net Change PBYIPositive Net Change VNDAPositive Net Change INDVPositive Net Change
biotechs earnings
Novavax (NVAX) Q4 Earnings & Sales Miss Estimates, Stock Tanks
by Zacks Equity Research
Novavax's (NVAX) fourth-quarter earnings and revenues miss estimates. Stock tanks on moderate revenue guidance for 2024.
NVAXNegative Net Change PBYIPositive Net Change VNDAPositive Net Change INDVPositive Net Change
biotechs earnings
Iovance's (IOVA) Q4 Earnings & Sales Fall Short of Estimates
by Zacks Equity Research
Iovance (IOVA) reports dismal earnings in the fourth quarter. Management is in the process of commercially launching the recently approved melanoma drug Amtagvi in the United States.
ACETPositive Net Change PBYIPositive Net Change ADMAPositive Net Change IOVANegative Net Change
biotechs earnings medical